Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed sentiment. While there is optimism with increased revenue guidance, gross margin expansion, and market growth, there are also concerns. The widening net loss and adjusted EBITDA loss, along with management's reluctance to provide specific guidance, could dampen investor sentiment. Additionally, the stock's reaction to strong gross margins and prescription growth suggests possible market skepticism. The Q&A insights highlight the company's strategic initiatives and market opportunities, but the financial uncertainties and competitive landscape may balance the positive aspects, resulting in a neutral outlook for the stock price.
Key Financial Performance
Revenue $24.6 million, a growth of 63% compared to the prior-year period. The increase was driven by a 58% year-over-year increase in prescriptions, market share gains with existing customers, activation of new accounts, expansion of the field team, and higher revenue per fit.
Gross Margin 52.6%, up 9 points year-over-year and 200 basis points sequentially. This marks the ninth consecutive quarter of sequential gross margin expansion. The improvement was due to attractive unit economics of the rental model, an increase in revenue per fit from more in-network patients, and a decline in cost per fit driven by volume leverage and cost improvement projects.
Operating Expenses $47.7 million in the third quarter, up from $27.1 million in the prior-year period. Excluding nonrecurring costs and stock-based compensation, operating expenses were $36.1 million compared to $24.8 million in the prior-year period. The increase was primarily due to investments in commercial expansion and public company costs.
Net Loss $34.2 million in the third quarter compared to $21.8 million in the prior-year period. The increase in net loss was attributed to higher operating expenses and investments in growth initiatives.
Adjusted EBITDA Loss $21.2 million in the third quarter compared to $16.3 million in the prior-year period. The increase was due to higher operating expenses and investments in commercial expansion.
Cash and Cash Equivalents $291 million as of January 31, which includes the net proceeds from the public equity offering in December.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ASSURE system: The ASSURE system demonstrated its effectiveness in detecting and responding to cardiac risks, including life-threatening arrhythmias, with updates to its algorithm to reduce false alarms and inappropriate shocks.
Biobeat collaboration: Kestra announced a strategic collaboration with Biobeat Technologies to integrate their FDA-cleared ambulatory blood pressure monitoring device into Kestra's product portfolio, enhancing diagnostic insights for cardiac recovery.
WCD market expansion: The WCD market is growing in the low mid-teens annually, with Kestra estimating it to become a multibillion-dollar market. Kestra's innovations and clinical evidence are driving increased adoption.
Sales territory expansion: Kestra expanded its sales territories to 100 and aims to reach 130 by the end of fiscal year 2026, targeting high-volume WCD prescription areas.
Revenue growth: Revenue increased by 63% year-over-year to $24.6 million in Q3, driven by a 58% rise in prescriptions and higher revenue per fit.
Gross margin improvement: Gross margin rose to 52.6%, marking the ninth consecutive quarter of sequential improvement, with a target of 70%+ in the coming years.
Reimbursement and payer network: Kestra became an approved provider for Florida's managed Medicaid and added to the federal supply schedule for the U.S. Department of Veterans Affairs, increasing in-network patient coverage to over 80%.
IPO and financial positioning: Kestra completed its IPO 12 months ago, fortified its balance sheet, and plans to file a shelf registration statement for corporate governance purposes.
Revenue guidance increase: Fiscal year 2026 revenue guidance was raised to $93 million, reflecting a 55% growth compared to fiscal year 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Underutilization of WCD Therapy: Despite evidence supporting the effectiveness of external defibrillation shocks, wearable cardioverter defibrillator (WCD) therapy remains underutilized, with 6 out of 7 eligible patients not being protected. This represents a challenge in expanding market adoption.
Regulatory and Reimbursement Challenges: Kestra has faced challenges in obtaining managed Medicaid provider numbers in key states like Florida, which has impacted their ability to serve a significant portion of Medicaid enrollees. Additionally, the company is working to bring more payers in-network, which is a lengthy process given the over 3,000 payers in the U.S.
Operational Costs and Losses: The company reported a GAAP net loss of $34.2 million in the third quarter, an increase from the prior-year period. Operating expenses have risen due to investments in commercial expansion and public company costs, which could strain financial resources.
Competitive Pressures: Kestra operates in a competitive market with an incumbent player. The need to differentiate its product and gain market share remains a challenge.
Economic and Market Expansion Risks: While the WCD market is expanding, Kestra is still in the early stages of market growth. The company’s ability to scale and capture a significant share of this multibillion-dollar market is uncertain.
Technological and Product Development Risks: The company is investing in new technologies and collaborations, such as the integration of Biobeat's technology. However, the success of these innovations in driving market share and improving patient outcomes is not guaranteed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Fiscal Year 2026: Kestra has increased its revenue guidance to $93 million, representing a 55% growth compared to fiscal year 2025. This is an increase from the prior guidance of $91 million and the initial guidance of $85 million.
Gross Margin Projections: Kestra expects steady and concrete increases in gross margin in the upcoming quarters, with a target of achieving 70%+ gross margins in the next few years. This will be driven by volume leverage, cost improvement projects, and the rental model's inherent unit economics.
Market Expansion and Growth: The WCD market is projected to grow into a multibillion-dollar market in the coming years. Kestra is in the early stages of market expansion and expects continued growth in prescriptions and market share.
Product Innovation and Differentiation: Kestra announced FDA approval for a new ASSURE algorithm update, which will reduce false alarms and inappropriate shocks. Additionally, a strategic collaboration with Biobeat Technologies aims to integrate advanced blood pressure monitoring into Kestra's product portfolio, further differentiating its offerings.
Sales Expansion: Kestra is expanding its sales organization, targeting 130 active sales territories by the end of fiscal year 2026, up from 100 at the end of calendar year 2025.
Reimbursement and Market Access: Kestra has become an approved Florida managed Medicaid provider and signed contracts with two of the state's largest managed Medicaid plans. Additionally, Kestra has been added to the federal supply schedule for the U.S. Department of Veterans Affairs, expanding access to a significant patient population.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's thoughts on the $133 million consensus for 2027?
A:The company does not comment on full-year guidance for 2027 until the end of the Q4 call. However, they feel confident about delivering top-tier med tech growth in 2027 and beyond.
Q:What is driving the acceleration in the WCD market growth?
A:The acceleration is driven by Kestra increasing its commercial team size, clinical results from both competitors and Kestra's studies highlighting higher risks in the patient population, and competitors realizing they need to expand the market due to Kestra taking market share.
Q:What contributed to the sequential bump in prescriptions?
A:The growth came from productivity improvements in base territory managers and new territory managers coming up the productivity curve. About 70-75% of the growth came from current market share shifts, and 25% came from new prescribers.
Q:Why might the stock be down despite strong gross margins and prescription growth?
A:The stock might be down due to expectations for a higher full-year guide. Management stated there are no pricing or competitive headwinds and emphasized their mid-50% year-over-year growth as a significant achievement.
Q:What is the impact of competition and new WCD products on Kestra's market share?
A:Kestra has not seen significant impact from competitors' new WCD products. Competitors focus on service levels and ease of business, while Kestra differentiates with its product.
Q:What is needed to get more physicians to prescribe WCDs?
A:Market growth will require updates to clinical guidelines. Kestra is working on publishing its ACE-PAS study to engage societies and clarify steps for guideline changes.
Q:What is the vision for the sales force size by fiscal 2027?
A:The company plans to double the sales force from 80 territories to 160 by fiscal 2027. They are considering whether to accelerate this growth further, as capital is not a constraint.
Q:Why did the conversion rate dip slightly in the recent quarter?
A:The dip is attributed to January deductible resets and claims held back for fair share servicing. However, the conversion rate has shown significant year-over-year improvement.
Q:What is the significance of obtaining a Medicaid license in Florida?
A:The Medicaid license removes a major barrier for Kestra's reps in Florida, allowing them to fully convert prescribers and increase market share. It will also positively impact gross margins.
Q:What is the impact of the FDA approval for Kestra's new algorithm?
A:The new algorithm reduces false alarm rates and inappropriate shock rates, improving patient compliance and safety. It further differentiates Kestra's product in the market.
Q:What are Kestra's plans for the Veterans Affairs network?
A:Kestra plans to roll out its federal supply schedule number territory by territory, enabling reps to serve VA institutions and expand market access.
Q:What is driving the sequential uptick in prescriptions?
A:The uptick is driven by investments in the commercial footprint, new reps, ACE-PAS data, medical education, and expanded roles for clinical specialists. Management believes the momentum will continue.
Q:How does territory expansion relate to revenue growth?
A:Revenue growth is supported by both territory expansion and productivity improvements in existing reps. The model does not rely solely on adding new reps for growth.
Q:What is the role of CapEx in Kestra's growth strategy?
A:CapEx spending is a leading indicator of confidence in revenue growth. Kestra plans to invest around $30 million annually in CapEx to support new units and maintain service levels.
Q:What is the cash burn rate, and how does it relate to future investments?
A:The cash burn rate was $28 million in the quarter, with $9 million for CapEx. Management expects a similar range for the next year, supporting territory expansion and other investments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2027 revenue, stating they would comment on full-year guidance at the end of the Q4 call. They also did not provide detailed explanations for the slight dip in conversion rates beyond general factors like deductible resets.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABPM patient
ACE PAS
AHA reminder
ASSURE WCD
ASSURE algorithm
ASSURE system
Affairs VA
Americans result
Biobeat FDA
Biobeat Technologies
Florida Medicaid
Medicaid plan
Medicaid provider
alert
blood pressure
calendar
clinician
collaboration Biobeat
day ASSURE
detection
engagement
episode
finding patient
heart
intervention
life shock
market mid
measurement
patient ASSURE
patient recovery
position
protection insight
reimbursement
result ACE
state
study finding
KMTS Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Unknown3-17
The earnings call presents a mixed sentiment. While there is optimism with increased revenue guidance, gross margin expansion, and market growth, there are also concerns. The widening net loss and adjusted EBITDA loss, along with management's reluctance to provide specific guidance, could dampen investor sentiment. Additionally, the stock's reaction to strong gross margins and prescription growth suggests possible market skepticism. The Q&A insights highlight the company's strategic initiatives and market opportunities, but the financial uncertainties and competitive landscape may balance the positive aspects, resulting in a neutral outlook for the stock price.
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Positive12-11
The earnings call reveals strong revenue growth, market expansion, and a strategic focus on innovation. Despite increased losses, cash reserves are robust. The Q&A highlights sustainable growth strategies and positive market reaction to clinical data. The company's guidance and strategic plans suggest a positive outlook, with expected gross margin expansion and increased prescription volumes. While there are uncertainties regarding guideline changes, the overall sentiment is positive, driven by strong financial metrics and optimistic guidance, likely leading to a stock price increase in the short term.
Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript
Unknown9-11
The earnings call presented mixed signals. While the company raised guidance and is optimistic about growth, financial metrics reveal increasing losses and operating expenses. The Q&A highlighted positive developments in in-network expansion and prescription growth, but also noted management's lack of detailed guidance on key strategic initiatives. The overall sentiment is balanced by the bullish outlook and ongoing investments, suggesting a neutral stock price movement in the short term.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
